Skip to content
Screener

CRISPR Therapeutics CRSP Grant — Revenue

Other product segments

Collaboration Revenue
$1M

Similar metrics at other companies

Kopin logo
KOPNGrant — Revenue
$3.44M+1,505%
Celldex Therapeutics logo
CLDXGrant — Revenue
$15K-97.9%
Kopin logo
KOPNGrant Income — Revenue
$3.44M+1,504%
Organogenesis Holdings Inc. logo
ORGOGrant — Revenue
$950K+320%
Blink Charging Co. logo
BLNKGrant And Fee Rebate — Revenue
$33K+3.1%
American Public Education logo
APEIInstructional services, net of grants and scholarships — Revenue
$158.86M+5.7%

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$5.07B-1.0%
Enterprise value$5.44B+5.6%
P/S1,236.1×+1,101×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:48 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204188
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Revenue:
Collaboration revenue$1,000
Grant revenue458865
Total revenue1,458865
Operating expenses:
Research and development68,57472,484
General and administrative17,18319,296
Collaboration expense, net45,94957,509

Item 1. Financial Statements

FAQ

What is CRISPR Therapeutics's grant — revenue?
CRISPR Therapeutics (CRSP) reported grant — revenue of $458K in Q1 2026.
How has CRISPR Therapeutics's grant — revenue changed year-over-year?
CRISPR Therapeutics's grant — revenue decreased by 47.1% year-over-year, from $865K to $458K.
What is the long-term trend for CRISPR Therapeutics's grant — revenue?
Over 4 years (2021 to 2025), CRISPR Therapeutics's grant — revenue has grown at a 16.9% compound annual growth rate (CAGR), from $1.88M to $3.51M.
What does grant — revenue mean?
This metric represents the revenue recognized from government or institutional grants and research contracts, excluding any associated tax assessments. It reflects the financial support received for specific research and development initiatives, serving as a key indicator of non-dilutive funding for early-stage therapeutic programs. This revenue stream highlights the company's ability to secure external validation and financial backing for its proprietary gene-editing technology platforms.

Ask your AI about CRISPR Therapeutics's grant — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude